[go: up one dir, main page]

FR2901135B1 - USE OF GLYCOLYSIS MODULATORS AS AGENTS REDUCING THE PROLIFERATION OF KERATINOCYTES - Google Patents

USE OF GLYCOLYSIS MODULATORS AS AGENTS REDUCING THE PROLIFERATION OF KERATINOCYTES

Info

Publication number
FR2901135B1
FR2901135B1 FR0651880A FR0651880A FR2901135B1 FR 2901135 B1 FR2901135 B1 FR 2901135B1 FR 0651880 A FR0651880 A FR 0651880A FR 0651880 A FR0651880 A FR 0651880A FR 2901135 B1 FR2901135 B1 FR 2901135B1
Authority
FR
France
Prior art keywords
glycolysis
keratinocytes
modulators
proliferation
agents reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0651880A
Other languages
French (fr)
Other versions
FR2901135A1 (en
Inventor
Lionel Breton
Josserand Michelle Rathman
Potter Isabelle De
Louis Hue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to FR0651880A priority Critical patent/FR2901135B1/en
Publication of FR2901135A1 publication Critical patent/FR2901135A1/en
Application granted granted Critical
Publication of FR2901135B1 publication Critical patent/FR2901135B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0651880A 2006-05-22 2006-05-22 USE OF GLYCOLYSIS MODULATORS AS AGENTS REDUCING THE PROLIFERATION OF KERATINOCYTES Active FR2901135B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0651880A FR2901135B1 (en) 2006-05-22 2006-05-22 USE OF GLYCOLYSIS MODULATORS AS AGENTS REDUCING THE PROLIFERATION OF KERATINOCYTES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0651880A FR2901135B1 (en) 2006-05-22 2006-05-22 USE OF GLYCOLYSIS MODULATORS AS AGENTS REDUCING THE PROLIFERATION OF KERATINOCYTES

Publications (2)

Publication Number Publication Date
FR2901135A1 FR2901135A1 (en) 2007-11-23
FR2901135B1 true FR2901135B1 (en) 2017-12-08

Family

ID=37571861

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0651880A Active FR2901135B1 (en) 2006-05-22 2006-05-22 USE OF GLYCOLYSIS MODULATORS AS AGENTS REDUCING THE PROLIFERATION OF KERATINOCYTES

Country Status (1)

Country Link
FR (1) FR2901135B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108653736A (en) * 2018-04-28 2018-10-16 中国人民解放军第二军医大学 Application of the M2 types pyruvate kinase as drug target in the drug for preparing prevention psoriasis

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093925A1 (en) * 2008-01-23 2009-07-30 United Technologies Ut Ag COSMETIC COMPOSITIONS COMPRISING 5-AMINO-L-β-D- RIBOFURANOSYL-LH-IMIDAZOLE-4-CARBOXAMIDE OR DERIVATIVES, OR SALTS THEREOF
FR3028857B1 (en) * 2014-11-26 2017-01-06 Oreal C-GLYCOSIDES DERIVED FROM AMINO ACIDS
CN106309458A (en) * 2016-07-28 2017-01-11 中南大学湘雅医院 Application of 2-deoxy-D-glucose and pharmaceutically acceptable salts thereof in preparation of medicines for treating psoriasis
CN113975255A (en) * 2021-09-16 2022-01-28 中国人民解放军西部战区总医院 Phloretin and application of chemical structure derivative thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684747A (en) * 1984-12-20 1987-08-04 Yale University N,N'-bis(sulfonyl)hydrazines having antineoplastic activity
US4849563A (en) * 1986-01-21 1989-07-18 Yale University Novel 1-alkyl-1-arenesulfonyl-2-alkoxycarbonylsulfenylhydrazines having antineoplastic activity
CA2406871A1 (en) * 2000-02-23 2001-08-30 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
BRPI0516453A (en) * 2004-10-07 2008-09-02 Pfizer Prod Inc benzoimidazole derivatives useful as antiproliferative agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108653736A (en) * 2018-04-28 2018-10-16 中国人民解放军第二军医大学 Application of the M2 types pyruvate kinase as drug target in the drug for preparing prevention psoriasis

Also Published As

Publication number Publication date
FR2901135A1 (en) 2007-11-23

Similar Documents

Publication Publication Date Title
ZA201001157B (en) Sulfonamides as trpm8 modulators
EP2178460A4 (en) CARTILAGE GRAFTS
EP2200550A4 (en) TOPICAL FORMULATIONS OF GLYCOPYRROLATE
EP2136768A4 (en) STRUCTURED COMPOSITIONS OF SURFACTANTS
PT2173944T (en) LOAD COMPOSITION
EP2361224A4 (en) USE OF DESALINATION WASTE
EP2140877A4 (en) NEW USE OF COCCIDIES
BRPI1012787A2 (en) "amylase polypeptides"
EP2276339A4 (en) ANTIMICROBIAL COMPOSITION AND USE
EP2438713A4 (en) DETERMINING SERVER USE
EP2171096A4 (en) CARBOXYLESTERASE-1 POLYMORPHISMS AND METHODS OF USE
ATE519836T1 (en) LIQUID WHITENESS MAINTAINING COMPOSITION
BRPI0716458A2 (en) VOLCANIZED COMPOSITION
EP1984325A4 (en) SULFONANILIDE ANALOGUES AS SELECTIVE MODULATORS OF AROMATASES
BRPI0813230A2 (en) CALICREIN MODULATORS 7
EP2349266A4 (en) Sulfonamide containing compounds and uses thereof
EP2051987A4 (en) USE OF CD83 IN POLYTHERAPIES
BRPI0815473A2 (en) STRUCTURED SOAP COMPOSITIONS
FR2896414B1 (en) MATIFYING COSMETIC COMPOSITION
EP2262365A4 (en) USE OF -THIO-2'-DEOXYNUCLEOSIDES AS ANTI-ORTHOPOXVIRUS AGENTS
BRPI0918579A2 (en) surfactant gel composition
BRPI0816154A2 (en) Replaced 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
EP2184063A4 (en) USE OF LÉONURINE AND COMPOSITIONS
FR2901135B1 (en) USE OF GLYCOLYSIS MODULATORS AS AGENTS REDUCING THE PROLIFERATION OF KERATINOCYTES
FR2915896B1 (en) COSMETIC COMPOSITION FOISONNEE

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19